首页 > 最新文献

British Journal of Pain最新文献

英文 中文
Acceptability of a proposed practice pharmacist-led review for opioid-treated patients with persistent pain: A qualitative study to inform intervention development 针对接受阿片类药物治疗的顽固性疼痛患者提出的由执业药师主导的审查的可接受性:为制定干预措施提供信息的定性研究
IF 1.8 Q4 CLINICAL NEUROLOGY Pub Date : 2023-12-19 DOI: 10.1177/20494637231221688
Nicola Cornwall, Charlotte Woodcock, Julie Ashworth, Sarah A Harrisson, L. Dikomitis, Simon White, T. Helliwell, Eleanor Hodgson, R. Knaggs, Tamar Pincus, M. Santer, Christian D Mallen, Clare Jinks
Regular review of patients prescribed opioids for persistent non-cancer pain (PCNP) is recommended but not routinely undertaken. The PROMPPT (Proactive clinical Review of patients taking Opioid Medicines long-term for persistent Pain led by clinical Pharmacists in primary care Teams) research programme aims to develop and test a pharmacist-led pain review (PROMPPT) to reduce inappropriate opioid use for persistent pain in primary care. This study explored the acceptability of the proposed PROMPPT review to inform early intervention development. Interviews ( n = 15) and an online discussion forum ( n = 31) with patients prescribed opioids for PCNP and interviews with pharmacists ( n = 13), explored acceptability of a proposed PROMPPT review. A prototype PROMPPT review was then tested and refined through 3 iterative cycles of in-practice testing (IPT) ( n = 3 practices, n = 3 practice pharmacists, n = 13 patients). Drawing on the Theoretical Framework of Acceptability (TFA), a framework was generated (including a priori TFA constructs) allowing for deductive and inductive thematic analysis to identify aspects of prospective and experienced acceptability. Patients felt uncertain about practice pharmacists delivering the proposed PROMPPT review leading to development of content for the invitation letter for IPT (introducing the pharmacist and outlining the aim of the review). After IPT, patients felt that pharmacists were suited to the role as they were knowledgeable and qualified. Pharmacists felt that the proposed reviews would be challenging. Although challenges were experienced during delivery of PROMPPT reviews, pharmacists found that they became easier to deliver with time, practise and experience. Recommendations for optimisations after IPT included development of the training to include examples of challenging consultations. Uptake of new healthcare interventions is influenced by perceptions of acceptability. Exploring prospective and experienced acceptability at multiple time points during early intervention development, led to mini-optimisations of the prototype PROMPPT review ahead of a non-randomised feasibility study.
建议对因持续性非癌性疼痛(PCNP)而处方阿片类药物的患者进行定期复查,但这并非常规做法。PROMPPT(由基层医疗团队中的临床药剂师牵头,对长期服用阿片类药物治疗顽固性疼痛的患者进行主动临床审查)研究项目旨在开发和测试一种由药剂师牵头的疼痛审查方法(PROMPPT),以减少基层医疗中因顽固性疼痛而不适当使用阿片类药物的情况。本研究探讨了建议的 PROMPPT 审查的可接受性,以便为早期干预措施的开发提供信息。通过对开具阿片类药物治疗 PCNP 的患者进行访谈(15 人)和在线讨论论坛(31 人),以及对药剂师进行访谈(13 人),探讨了建议的 PROMPPT 审查的可接受性。然后,通过 3 个迭代周期的实践测试 (IPT),对 PROMPPT 审查原型进行了测试和改进(3 个实践,3 个实践药剂师,13 名患者)。借鉴可接受性理论框架 (TFA),建立了一个框架(包括先验的 TFA 构建),允许进行演绎和归纳专题分析,以确定预期可接受性和经验可接受性的各个方面。患者对执业药剂师提供建议的 PROMPPT 审查感到不确定,这导致了 IPT 邀请函内容的制定(介绍药剂师并概述审查目的)。在 IPT 结束后,患者认为药剂师知识渊博、资质合格,适合担任这一角色。药剂师认为建议的复查具有挑战性。尽管在实施 PROMPPT 审查过程中遇到了挑战,但药剂师发现,随着时间的推移、实践和经验的积累,这些审查变得越来越容易实施。IPT 之后的优化建议包括开展培训,以纳入具有挑战性的咨询实例。对新医疗干预措施的接受程度受可接受性观念的影响。在早期干预开发过程中,在多个时间点探索预期和经验的可接受性,有助于在非随机可行性研究之前对 PROMPPT 审查原型进行小型优化。
{"title":"Acceptability of a proposed practice pharmacist-led review for opioid-treated patients with persistent pain: A qualitative study to inform intervention development","authors":"Nicola Cornwall, Charlotte Woodcock, Julie Ashworth, Sarah A Harrisson, L. Dikomitis, Simon White, T. Helliwell, Eleanor Hodgson, R. Knaggs, Tamar Pincus, M. Santer, Christian D Mallen, Clare Jinks","doi":"10.1177/20494637231221688","DOIUrl":"https://doi.org/10.1177/20494637231221688","url":null,"abstract":"Regular review of patients prescribed opioids for persistent non-cancer pain (PCNP) is recommended but not routinely undertaken. The PROMPPT (Proactive clinical Review of patients taking Opioid Medicines long-term for persistent Pain led by clinical Pharmacists in primary care Teams) research programme aims to develop and test a pharmacist-led pain review (PROMPPT) to reduce inappropriate opioid use for persistent pain in primary care. This study explored the acceptability of the proposed PROMPPT review to inform early intervention development. Interviews ( n = 15) and an online discussion forum ( n = 31) with patients prescribed opioids for PCNP and interviews with pharmacists ( n = 13), explored acceptability of a proposed PROMPPT review. A prototype PROMPPT review was then tested and refined through 3 iterative cycles of in-practice testing (IPT) ( n = 3 practices, n = 3 practice pharmacists, n = 13 patients). Drawing on the Theoretical Framework of Acceptability (TFA), a framework was generated (including a priori TFA constructs) allowing for deductive and inductive thematic analysis to identify aspects of prospective and experienced acceptability. Patients felt uncertain about practice pharmacists delivering the proposed PROMPPT review leading to development of content for the invitation letter for IPT (introducing the pharmacist and outlining the aim of the review). After IPT, patients felt that pharmacists were suited to the role as they were knowledgeable and qualified. Pharmacists felt that the proposed reviews would be challenging. Although challenges were experienced during delivery of PROMPPT reviews, pharmacists found that they became easier to deliver with time, practise and experience. Recommendations for optimisations after IPT included development of the training to include examples of challenging consultations. Uptake of new healthcare interventions is influenced by perceptions of acceptability. Exploring prospective and experienced acceptability at multiple time points during early intervention development, led to mini-optimisations of the prototype PROMPPT review ahead of a non-randomised feasibility study.","PeriodicalId":46585,"journal":{"name":"British Journal of Pain","volume":" 38","pages":""},"PeriodicalIF":1.8,"publicationDate":"2023-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138961413","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Intravenous S-ketamine’s analgesic efficacy in third molar surgery. A randomized placebo-controlled double-blind clinical trial 静脉注射S-氯胺酮对第三磨牙手术的镇痛效果。随机安慰剂对照双盲临床试验
IF 1.8 Q4 CLINICAL NEUROLOGY Pub Date : 2023-12-15 DOI: 10.1177/20494637231222327
Lars B Eriksson, Torsten Gordh, Rolf Karlsten, Riccardo LoMartire, Andreas Thor, Åke Tegelberg
In most cases, a combination of paracetamol and ibuprofen are the optimal treatment for postoperative pain in third molar surgery. If stronger analgesia is required, opioids are traditionally administered. In day-case, surgery; however, opioids should be avoided. Thus, the anaesthetic agent S-ketamine in analgesic doses might be preferred. The study was designed as a randomized placebo-controlled double-blind clinical trial. The study enrolled healthy subjects according to the American Society of Anaesthesiologists classification; I or II (ASA), aged 18 to 44 years, with a body weight between 50 and 100 kg. The patients were randomized into three groups where two doses of S-ketamine were compared (high: 0.25 mg/kg or low: 0.125 mg/kg) with placebo (saline). A primary outcome of the study was that VAS at 4 h postoperatively, showed no significant difference between the placebo and high-dose S-ketamine group or in the low-dose group. We found a significant difference between the groups for the first 24 h, with a lower VAS-score in the high-dose S-ketamine group. The time to when 50% had taken their first rescue medication was 12 min later in the high-dose ketamine group. Pre-emptive S-ketamine 0.25 mg/kg gave a global significant reduction of pain by VAS during the first 24 h postoperatively. The time from end of surgery to first rescue medication were longer in the high-dose ketamine group compared to both low-dose ketamine and placebo groups.
在大多数情况下,扑热息痛和布洛芬是治疗第三磨牙手术术后疼痛的最佳药物。如果需要更强的镇痛效果,传统上会使用阿片类药物。但在日间手术中,应避免使用阿片类药物。因此,镇痛剂量的麻醉剂 S-Ketamine 可能是首选。该研究设计为随机安慰剂对照双盲临床试验。根据美国麻醉医师协会的分类,该研究招募了年龄在 18 至 44 岁之间、体重在 50 至 100 公斤之间的 I 类或 II 类(ASA)健康受试者。患者被随机分为三组,将两种剂量的S-氯胺酮(高剂量:0.25毫克/千克或低剂量:0.125毫克/千克)与安慰剂(生理盐水)进行比较。研究的主要结果是,术后 4 小时的 VAS 显示,安慰剂组和高剂量 S-Ketamine 组以及低剂量组之间没有显著差异。我们发现,在最初的 24 小时内,各组之间存在明显差异,高剂量 S-Ketamine 组的 VAS 评分较低。在大剂量氯胺酮组中,50%的患者服用第一种抢救药物的时间要晚12分钟。术前使用0.25毫克/千克的S-氯胺酮可在术后24小时内显著降低VAS评分。与低剂量氯胺酮组和安慰剂组相比,高剂量氯胺酮组从手术结束到首次使用抢救药物的时间更长。
{"title":"Intravenous S-ketamine’s analgesic efficacy in third molar surgery. A randomized placebo-controlled double-blind clinical trial","authors":"Lars B Eriksson, Torsten Gordh, Rolf Karlsten, Riccardo LoMartire, Andreas Thor, Åke Tegelberg","doi":"10.1177/20494637231222327","DOIUrl":"https://doi.org/10.1177/20494637231222327","url":null,"abstract":"In most cases, a combination of paracetamol and ibuprofen are the optimal treatment for postoperative pain in third molar surgery. If stronger analgesia is required, opioids are traditionally administered. In day-case, surgery; however, opioids should be avoided. Thus, the anaesthetic agent S-ketamine in analgesic doses might be preferred. The study was designed as a randomized placebo-controlled double-blind clinical trial. The study enrolled healthy subjects according to the American Society of Anaesthesiologists classification; I or II (ASA), aged 18 to 44 years, with a body weight between 50 and 100 kg. The patients were randomized into three groups where two doses of S-ketamine were compared (high: 0.25 mg/kg or low: 0.125 mg/kg) with placebo (saline). A primary outcome of the study was that VAS at 4 h postoperatively, showed no significant difference between the placebo and high-dose S-ketamine group or in the low-dose group. We found a significant difference between the groups for the first 24 h, with a lower VAS-score in the high-dose S-ketamine group. The time to when 50% had taken their first rescue medication was 12 min later in the high-dose ketamine group. Pre-emptive S-ketamine 0.25 mg/kg gave a global significant reduction of pain by VAS during the first 24 h postoperatively. The time from end of surgery to first rescue medication were longer in the high-dose ketamine group compared to both low-dose ketamine and placebo groups.","PeriodicalId":46585,"journal":{"name":"British Journal of Pain","volume":"7 2","pages":""},"PeriodicalIF":1.8,"publicationDate":"2023-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139000887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The efficacy, acceptability and safety of acceptance and commitment therapy for fibromyalgia – a systematic review and meta-analysis 接受和承诺疗法治疗纤维肌痛的疗效、可接受性和安全性--系统回顾和荟萃分析
IF 1.8 Q4 CLINICAL NEUROLOGY Pub Date : 2023-12-12 DOI: 10.1177/20494637231221451
Florence Eastwood, Emma Godfrey
Fibromyalgia (FM) is a chronic pain disorder characterised by widespread pain, fatigue and cognitive symptoms. Acceptance and commitment therapy (ACT) aims to improve psychological flexibility and has been found to be beneficial in treating chronic pain; however, there are few studies evaluating its efficacy in treating FM. This systematic review and meta-analysis evaluated the efficacy of acceptance and commitment therapy in patients with fibromyalgia. PubMed, Embase and PsychInfo databases were searched. Randomised Controlled Trials (RCTs) were eligible for inclusion if participants had FM, and the intervention was based on the ACT framework/model, and not combined with any other active therapy; any non-ACT control was accepted. A meta-analysis was performed, with the primary outcomes pain acceptance (chronic pain acceptance questionnaire, CPAQ), health-related quality of life (fibromyalgia impact questionnaire, FIQ), attrition rate and frequency of adverse events, and the secondary outcomes pain intensity, disability, depression, anxiety, and fatigue. Six RCTs, with a total of 384, mostly-female, participants were included, with ACT being delivered online, in a group setting, or one-to-one. ACT was superior to controls in improving FIQ score at post-intervention (SMD −1.05, 95% CI −2.02, −0.09) and follow-up (SMD −1.43, 95% CI −2.17, −0.69) and CPAQ post-intervention (SMD 1.05, 95% CI 0.61, 1.49) and at follow-up (SMD 0.95, 95% CI 0.40, 1.49). Attrition was below 20% in 4/6 studies and no adverse events were reported as attributable to ACT. All secondary outcomes showed large-to-moderate pooled effect estimates post-intervention, indicating improvement in anxiety, depression, pain and disability. Fatigue also improved, with a large negative effect. The results suggest ACT improved outcomes in patients with FM: there was an overall improvement in all outcomes post-intervention, with most maintained at follow-up. This review was, however, limited by the small body of evidence and differing methodologies of included studies.
纤维肌痛(FM)是一种慢性疼痛疾病,以广泛性疼痛、疲劳和认知症状为特征。接纳与承诺疗法(ACT)旨在提高心理灵活性,已被发现对治疗慢性疼痛有益;然而,很少有研究评估其对治疗纤维肌痛的疗效。本系统综述和荟萃分析评估了接受和承诺疗法对纤维肌痛患者的疗效。检索了 PubMed、Embase 和 PsychInfo 数据库。只要参与者患有纤维肌痛,干预措施基于接纳与承诺疗法的框架/模式,且未与任何其他积极疗法相结合,任何非接纳与承诺疗法的对照研究均可纳入随机对照试验(RCT)。荟萃分析的主要结果为疼痛接受度(慢性疼痛接受度问卷,CPAQ)、健康相关生活质量(纤维肌痛影响问卷,FIQ)、减员率和不良事件频率,次要结果为疼痛强度、残疾、抑郁、焦虑和疲劳。六项研究共纳入了 384 名参与者,其中大部分为女性,ACT 采用在线、小组或一对一的方式进行。在改善干预后(SMD-1.05,95% CI -2.02,-0.09)和随访(SMD-1.43,95% CI -2.17,-0.69)的FIQ得分以及干预后(SMD 1.05,95% CI 0.61,1.49)和随访(SMD 0.95,95% CI 0.40,1.49)的CPAQ得分方面,ACT优于对照组。4/6项研究的自然减员率低于20%,无不良事件报告可归因于ACT。干预后,所有次要结果都显示出大到中等的集合效应估计值,表明焦虑、抑郁、疼痛和残疾状况有所改善。疲劳感也有所改善,并产生了较大的负效应。结果表明,ACT 可改善 FM 患者的预后:干预后所有预后均有整体改善,且大部分在随访时保持不变。然而,由于纳入研究的证据较少且研究方法各不相同,该综述受到了限制。
{"title":"The efficacy, acceptability and safety of acceptance and commitment therapy for fibromyalgia – a systematic review and meta-analysis","authors":"Florence Eastwood, Emma Godfrey","doi":"10.1177/20494637231221451","DOIUrl":"https://doi.org/10.1177/20494637231221451","url":null,"abstract":"Fibromyalgia (FM) is a chronic pain disorder characterised by widespread pain, fatigue and cognitive symptoms. Acceptance and commitment therapy (ACT) aims to improve psychological flexibility and has been found to be beneficial in treating chronic pain; however, there are few studies evaluating its efficacy in treating FM. This systematic review and meta-analysis evaluated the efficacy of acceptance and commitment therapy in patients with fibromyalgia. PubMed, Embase and PsychInfo databases were searched. Randomised Controlled Trials (RCTs) were eligible for inclusion if participants had FM, and the intervention was based on the ACT framework/model, and not combined with any other active therapy; any non-ACT control was accepted. A meta-analysis was performed, with the primary outcomes pain acceptance (chronic pain acceptance questionnaire, CPAQ), health-related quality of life (fibromyalgia impact questionnaire, FIQ), attrition rate and frequency of adverse events, and the secondary outcomes pain intensity, disability, depression, anxiety, and fatigue. Six RCTs, with a total of 384, mostly-female, participants were included, with ACT being delivered online, in a group setting, or one-to-one. ACT was superior to controls in improving FIQ score at post-intervention (SMD −1.05, 95% CI −2.02, −0.09) and follow-up (SMD −1.43, 95% CI −2.17, −0.69) and CPAQ post-intervention (SMD 1.05, 95% CI 0.61, 1.49) and at follow-up (SMD 0.95, 95% CI 0.40, 1.49). Attrition was below 20% in 4/6 studies and no adverse events were reported as attributable to ACT. All secondary outcomes showed large-to-moderate pooled effect estimates post-intervention, indicating improvement in anxiety, depression, pain and disability. Fatigue also improved, with a large negative effect. The results suggest ACT improved outcomes in patients with FM: there was an overall improvement in all outcomes post-intervention, with most maintained at follow-up. This review was, however, limited by the small body of evidence and differing methodologies of included studies.","PeriodicalId":46585,"journal":{"name":"British Journal of Pain","volume":"49 19","pages":""},"PeriodicalIF":1.8,"publicationDate":"2023-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139006867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Taking the pain out of pain. 从痛苦中解脱出来。
IF 1.8 Q4 CLINICAL NEUROLOGY Pub Date : 2023-12-01 Epub Date: 2023-10-18 DOI: 10.1177/20494637231208167
Catharine Montgomery, Helen M Poole, Emma Begley, Yasir Abbasi
{"title":"Taking the pain out of pain.","authors":"Catharine Montgomery, Helen M Poole, Emma Begley, Yasir Abbasi","doi":"10.1177/20494637231208167","DOIUrl":"https://doi.org/10.1177/20494637231208167","url":null,"abstract":"","PeriodicalId":46585,"journal":{"name":"British Journal of Pain","volume":"17 6","pages":"514-518"},"PeriodicalIF":1.8,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10642502/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134650213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Management of trigeminal neuralgia: A multi-centre case study in general practice. 三叉神经痛的治疗:全科多中心病例研究
IF 1.3 Q4 CLINICAL NEUROLOGY Pub Date : 2023-12-01 Epub Date: 2023-09-01 DOI: 10.1177/20494637231199332
Zofia J Zakrzewska, Parinaz Hosseini-Ashrafi, Ishrat Hussain, Zachary James Moulder, Jithu Subhash, Melissa Tan, Martin Ewart Johnson, Joanna M Zakrzewska

Background and aims: Patients often first present with symptoms of trigeminal neuralgia (TN) to primary care. However, there has been little research to determine whether the diagnosis and management of this condition is carried out according to current guidelines. Furthermore, there is little up-to-date information regarding the prevalence of TN in the UK. The aim is to estimate the prevalence of TN and to audit the diagnosis and management process of TN in primary care.

Methods: Between 2019 and 2020 a search was made at five UK GP practices with a total patient population of 55,842 using EMIS and SystmOne patient record systems to review patient consultations to identify patients coded with TN or facial pain (FP). These records were reviewed to ascertain the basis for diagnosis, management in primary care and referral to secondary care.

Results: 157 patients were identified; 54 coded with FP and 103 with TN. These results indicate a prevalence of 22.3 in 10,000. There was no difference in documented symptoms between the two groups. Seven patients had all ICDH3 criteria recorded, with two meeting the requirements for TN diagnosis. 58.8% of patients with TN were started on carbamazepine, the current gold standard treatment, compared with 16.7% in the FP group. 38.2% of TN patients were referred to a range of different specialities.

Conclusion: The prevalence of TN may be higher than previously thought. Key diagnostic criteria are often omitted, leading to potential misdiagnosis or delays in diagnosis. Relatively few referrals are made, though all patients should be considered for imaging.

患者通常首先以三叉神经痛(TN)症状就诊。然而,很少有研究来确定这种情况的诊断和管理是否根据目前的指导方针进行。此外,几乎没有关于TN在英国流行的最新信息。目的是估计TN的患病率,并审计初级保健中TN的诊断和管理过程。在2019年至2020年期间,研究人员使用EMIS和SystmOne患者记录系统对5家英国全科医生诊所进行了搜索,总患者人数为55,842人,以审查患者咨询,以识别编码为TN或面部疼痛(FP)的患者。对这些记录进行了审查,以确定诊断、初级保健管理和转介到二级保健的基础。确认157例患者;54个编码FP, 103个编码TN。这些结果表明患病率为22.3 / 10000。两组之间的记录症状没有差异。7例患者全部符合ICDH3标准,2例符合TN诊断要求。58.8%的TN患者开始使用卡马西平,这是目前的金标准治疗,而FP组的这一比例为16.7%。38.2%的TN患者被转诊到不同的专科。TN的流行率可能比以前认为的要高。关键的诊断标准往往被忽略,导致潜在的误诊或延误诊断。虽然所有患者都应考虑影像学检查,但转诊病例相对较少。
{"title":"Management of trigeminal neuralgia: A multi-centre case study in general practice.","authors":"Zofia J Zakrzewska, Parinaz Hosseini-Ashrafi, Ishrat Hussain, Zachary James Moulder, Jithu Subhash, Melissa Tan, Martin Ewart Johnson, Joanna M Zakrzewska","doi":"10.1177/20494637231199332","DOIUrl":"10.1177/20494637231199332","url":null,"abstract":"<p><strong>Background and aims: </strong>Patients often first present with symptoms of trigeminal neuralgia (TN) to primary care. However, there has been little research to determine whether the diagnosis and management of this condition is carried out according to current guidelines. Furthermore, there is little up-to-date information regarding the prevalence of TN in the UK. The aim is to estimate the prevalence of TN and to audit the diagnosis and management process of TN in primary care.</p><p><strong>Methods: </strong>Between 2019 and 2020 a search was made at five UK GP practices with a total patient population of 55,842 using EMIS and SystmOne patient record systems to review patient consultations to identify patients coded with TN or facial pain (FP). These records were reviewed to ascertain the basis for diagnosis, management in primary care and referral to secondary care.</p><p><strong>Results: </strong>157 patients were identified; 54 coded with FP and 103 with TN. These results indicate a prevalence of 22.3 in 10,000. There was no difference in documented symptoms between the two groups. Seven patients had all ICDH3 criteria recorded, with two meeting the requirements for TN diagnosis. 58.8% of patients with TN were started on carbamazepine, the current gold standard treatment, compared with 16.7% in the FP group. 38.2% of TN patients were referred to a range of different specialities.</p><p><strong>Conclusion: </strong>The prevalence of TN may be higher than previously thought. Key diagnostic criteria are often omitted, leading to potential misdiagnosis or delays in diagnosis. Relatively few referrals are made, though all patients should be considered for imaging.</p>","PeriodicalId":46585,"journal":{"name":"British Journal of Pain","volume":"1 1","pages":"606-612"},"PeriodicalIF":1.3,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10642494/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42351598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Understanding the lived experience of chronic pain: A systematic review and synthesis of qualitative evidence syntheses. 理解慢性疼痛的生活经验:一个系统的评价和定性证据综合。
IF 1.8 Q4 CLINICAL NEUROLOGY Pub Date : 2023-12-01 Epub Date: 2023-08-25 DOI: 10.1177/20494637231196426
Simon van Rysewyk, Renée Blomkvist, Antony Chuter, Rhea Crighton, Fiona Hodson, David Roomes, Blair H Smith, Francine Toye

Background: Although multiple measures of the causes and consequences of chronic non-cancer pain (CNCP) are available and can inform pain management, no quantitative summary of these measures can describe the meaning of pain for a patient. The lived experience of pain tends to be a blind spot in pain management. This study aimed to: (1) integrate qualitative research investigating the lived experience of a range of CNCP conditions; (2) establish common qualitative themes in CNCP experience; and (3) evaluate the relevance of our results through a survey questionnaire based on these themes, administered across the United Kingdom.

Methods: Four bibliographic databases were searched from inception to February 2021 to identify Qualitative Evidence Syntheses (QES) that investigated the lived experience of CNCP and its impact on everyday life and activities. Themes and trends were derived by thematic qualitative analysis in collaboration with two patient and public involvement representatives who co-created twenty survey statements. The survey was developed for testing the QES themes for validity in people living with pain.

Results: The research team identified and screened 1323 titles, and considered 86 abstracts, including 20 in the final review. Eight themes were developed from the study findings: (1) my pain gives rise to negative emotions; (2) changes to my life and to myself; (3) adapting to my new normal; (4) effects of my pain management strategies; (5) hiding and showing my pain; (6) medically explaining my pain; (7) relationships to those around me; and (8) working while in pain. Each theme gave rise to one or two survey questions. The survey was shared with members of the UK pain community over a 2-week period in November 2021, and was completed by 1219 people, largely confirming the above themes.

Conclusion/implications: This study provides a validated summary of the lived experience of CNCP. It highlights the adverse nature, complications, and consequences of living with CNCP in the UK and the multiple shortcomings in the ways in which pain is addressed by others in the UK. Our findings are consistent with published meta-ethnographies on chronic non-malignant musculoskeletal pain and chronic low-back pain. Despite the underrepresentation of qualitative research in the pain literature compared to quantitative approaches, for understanding the complexity of the lived experience of pain, qualitative research is an essential tool.

背景:虽然对慢性非癌性疼痛(CNCP)的原因和后果有多种测量方法,可以为疼痛管理提供信息,但这些测量方法的定量总结不能描述患者疼痛的意义。对疼痛的亲身体验往往是疼痛管理的盲点。本研究旨在:(1)整合质性研究,调查一系列CNCP状况的生活经验;(2)在CNCP经验中建立共同的定性主题;(3)通过基于这些主题的调查问卷评估我们的结果的相关性,在英国进行管理。方法:从建立到2021年2月,检索了四个书目数据库,以确定定性证据综合(QES),调查CNCP的生活经历及其对日常生活和活动的影响。主题和趋势是通过专题定性分析与两位患者和公众参与代表合作得出的,他们共同编写了20份调查声明。该调查是为了测试QES主题在疼痛患者中的有效性而开发的。结果:研究小组共筛选了1323个题目,审阅了86篇摘要,其中最终审稿20篇。从研究结果中发展出八个主题:(1)我的痛苦引起了负面情绪;(2)改变我的生活和我自己;(3)适应我的新常态;(4)疼痛管理策略的效果;(5)隐藏和展示我的痛苦;(6)从医学上解释我的疼痛;(7)与周围人的关系;(8)在痛苦中工作。每个主题都有一两个调查问题。该调查于2021年11月与英国疼痛社区的成员进行了为期两周的分享,共有1219人完成,在很大程度上证实了上述主题。结论/意义:本研究提供了CNCP生活经验的有效总结。它强调了在英国与CNCP一起生活的不良性质、并发症和后果,以及在英国其他人解决疼痛的方式中的多种缺点。我们的研究结果与已发表的关于慢性非恶性肌肉骨骼疼痛和慢性腰痛的元人种志一致。尽管与定量方法相比,定性研究在疼痛文献中的代表性不足,但为了理解疼痛生活经验的复杂性,定性研究是必不可少的工具。
{"title":"Understanding the lived experience of chronic pain: A systematic review and synthesis of qualitative evidence syntheses.","authors":"Simon van Rysewyk, Renée Blomkvist, Antony Chuter, Rhea Crighton, Fiona Hodson, David Roomes, Blair H Smith, Francine Toye","doi":"10.1177/20494637231196426","DOIUrl":"10.1177/20494637231196426","url":null,"abstract":"<p><strong>Background: </strong>Although multiple measures of the causes and consequences of chronic non-cancer pain (CNCP) are available and can inform pain management, no quantitative summary of these measures can describe the meaning of pain for a patient. The lived experience of pain tends to be a blind spot in pain management. This study aimed to: (1) integrate qualitative research investigating the lived experience of a range of CNCP conditions; (2) establish common qualitative themes in CNCP experience; and (3) evaluate the relevance of our results through a survey questionnaire based on these themes, administered across the United Kingdom.</p><p><strong>Methods: </strong>Four bibliographic databases were searched from inception to February 2021 to identify Qualitative Evidence Syntheses (QES) that investigated the lived experience of CNCP and its impact on everyday life and activities. Themes and trends were derived by thematic qualitative analysis in collaboration with two patient and public involvement representatives who co-created twenty survey statements. The survey was developed for testing the QES themes for validity in people living with pain.</p><p><strong>Results: </strong>The research team identified and screened 1323 titles, and considered 86 abstracts, including 20 in the final review. Eight themes were developed from the study findings: (1) my pain gives rise to negative emotions; (2) changes to my life and to myself; (3) adapting to my new normal; (4) effects of my pain management strategies; (5) hiding and showing my pain; (6) medically explaining my pain; (7) relationships to those around me; and (8) working while in pain. Each theme gave rise to one or two survey questions. The survey was shared with members of the UK pain community over a 2-week period in November 2021, and was completed by 1219 people, largely confirming the above themes.</p><p><strong>Conclusion/implications: </strong>This study provides a validated summary of the lived experience of CNCP. It highlights the adverse nature, complications, and consequences of living with CNCP in the UK and the multiple shortcomings in the ways in which pain is addressed by others in the UK. Our findings are consistent with published meta-ethnographies on chronic non-malignant musculoskeletal pain and chronic low-back pain. Despite the underrepresentation of qualitative research in the pain literature compared to quantitative approaches, for understanding the complexity of the lived experience of pain, qualitative research is an essential tool.</p>","PeriodicalId":46585,"journal":{"name":"British Journal of Pain","volume":"17 6","pages":"592-605"},"PeriodicalIF":1.8,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10642495/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134650214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Does opioid therapy enhance quality of life in patients suffering from chronic non-malignant pain? A systematic review and meta-analysis 阿片类药物治疗能否提高慢性非恶性疼痛患者的生活质量?系统回顾和荟萃分析
IF 1.8 Q4 CLINICAL NEUROLOGY Pub Date : 2023-11-26 DOI: 10.1177/20494637231216352
Karl V. L. Kraft, Teresa Backmund, Leopold Eberhart, Ann-Kristin Schubert, Hanns-Christian Dinges, Maria K. Hagen, Markus Gehling
Chronic pain is associated with a poor health-related quality of life (HRQL). Whereas the prescription rate of opioids increased during the last decades, their use in chronic non-malignant pain remains unclear. However, there is currently no clinical consensus or evidence-based guidelines that consider the long-term effects of opioid therapy on HRQL in patients with chronic non-cancer pain. This systematic review aims to address the question of whether opioid therapy improves HRQL in patients with chronic non-malignant pain and provide some guidance to practitioners. PubMed, EMBASE and CENTRAL were searched in June 2020 for double-blind, randomized trials (RCTs), comparing opioid therapy to placebo and assessed a HRQL questionnaire. The review comprises a qualitative vote counting approach and a meta-analysis of the Short Form Health Survey (SF-36), EQ-5D questionnaire and the pain interference scale of the Brief pain inventory (BPI). 35 RCTs were included, of which the majority reported a positive effect of opioids for the EQ-5D, the BPI and the physical component score (PCS) of the SF-36 compared to placebo. The meta-analysis of the PCS showed a mean difference of 1.82 [confidence interval: 1.32, 2.32], the meta-analysis of the EQ-5D proved a significant advantage of 0.06 [0.00, 0.12]. In the qualitative analysis of the mental component score (MCS) of the SF-36, no positive or negative trend was seen. No significant differences were seen in the MCS (MD: 0.65 [-0.43, 1.73]). A slightly higher premature dropout rate was found in the opioid group (risk difference: 0.04 [0.00, 0.07], p = .07). The body of evidence is graded as low to medium. Opioids have a statistically significant, but small and clinical not relevant effect on the physical dimensions of HRQL, whereas there is no effect on mental dimensions of HRQL in patients with chronic non-malignant pain during the initial months of treatment. In clinical practice, opioid prescriptions for chronic non-cancer pain should be individually assessed as their broad efficacy in improving quality of life is not confirmed. The duration of opioid treatment should be determined carefully, as this review primarily focuses on the initial months of therapy.
慢性疼痛与健康相关的生活质量(HRQL)低下有关。虽然阿片类药物的处方率在过去几十年中有所上升,但其在慢性非恶性疼痛中的应用仍不明确。然而,目前还没有临床共识或循证指南考虑阿片类药物治疗对慢性非癌症疼痛患者的 HRQL 的长期影响。本系统综述旨在探讨阿片类药物治疗是否能改善慢性非恶性疼痛患者的 HRQL,并为从业人员提供一些指导。本文于 2020 年 6 月在 PubMed、EMBASE 和 CENTRAL 上检索了双盲、随机试验 (RCT),这些试验将阿片类药物疗法与安慰剂进行了比较,并对 HRQL 问卷进行了评估。综述包括定性计票方法和对简表健康调查(SF-36)、EQ-5D 问卷和简明疼痛量表(BPI)的疼痛干扰量表进行的荟萃分析。共纳入了 35 项研究性临床试验,其中大多数报告称,与安慰剂相比,阿片类药物对 EQ-5D、BPI 和 SF-36 的身体成分评分(PCS)有积极影响。PCS的荟萃分析表明平均差异为1.82[置信区间:1.32,2.32],EQ-5D的荟萃分析表明显著优势为0.06[0.00,0.12]。在对 SF-36 心理成分得分(MCS)的定性分析中,未发现正负趋势。在 MCS 方面没有发现明显差异(MD:0.65 [-0.43, 1.73])。阿片类药物组的过早辍学率略高(风险差异:0.04 [0.00, 0.07],P = .07)。证据等级为中低。阿片类药物对慢性非恶性疼痛患者的身体方面的 HRQL 有统计学意义,但影响较小,与临床无关,而对治疗最初几个月的精神方面的 HRQL 没有影响。在临床实践中,由于阿片类药物在改善生活质量方面的广泛疗效尚未得到证实,因此对慢性非癌症疼痛患者的阿片类药物处方应进行单独评估。应谨慎确定阿片类药物治疗的持续时间,因为本综述主要关注治疗的最初几个月。
{"title":"Does opioid therapy enhance quality of life in patients suffering from chronic non-malignant pain? A systematic review and meta-analysis","authors":"Karl V. L. Kraft, Teresa Backmund, Leopold Eberhart, Ann-Kristin Schubert, Hanns-Christian Dinges, Maria K. Hagen, Markus Gehling","doi":"10.1177/20494637231216352","DOIUrl":"https://doi.org/10.1177/20494637231216352","url":null,"abstract":"Chronic pain is associated with a poor health-related quality of life (HRQL). Whereas the prescription rate of opioids increased during the last decades, their use in chronic non-malignant pain remains unclear. However, there is currently no clinical consensus or evidence-based guidelines that consider the long-term effects of opioid therapy on HRQL in patients with chronic non-cancer pain. This systematic review aims to address the question of whether opioid therapy improves HRQL in patients with chronic non-malignant pain and provide some guidance to practitioners. PubMed, EMBASE and CENTRAL were searched in June 2020 for double-blind, randomized trials (RCTs), comparing opioid therapy to placebo and assessed a HRQL questionnaire. The review comprises a qualitative vote counting approach and a meta-analysis of the Short Form Health Survey (SF-36), EQ-5D questionnaire and the pain interference scale of the Brief pain inventory (BPI). 35 RCTs were included, of which the majority reported a positive effect of opioids for the EQ-5D, the BPI and the physical component score (PCS) of the SF-36 compared to placebo. The meta-analysis of the PCS showed a mean difference of 1.82 [confidence interval: 1.32, 2.32], the meta-analysis of the EQ-5D proved a significant advantage of 0.06 [0.00, 0.12]. In the qualitative analysis of the mental component score (MCS) of the SF-36, no positive or negative trend was seen. No significant differences were seen in the MCS (MD: 0.65 [-0.43, 1.73]). A slightly higher premature dropout rate was found in the opioid group (risk difference: 0.04 [0.00, 0.07], p = .07). The body of evidence is graded as low to medium. Opioids have a statistically significant, but small and clinical not relevant effect on the physical dimensions of HRQL, whereas there is no effect on mental dimensions of HRQL in patients with chronic non-malignant pain during the initial months of treatment. In clinical practice, opioid prescriptions for chronic non-cancer pain should be individually assessed as their broad efficacy in improving quality of life is not confirmed. The duration of opioid treatment should be determined carefully, as this review primarily focuses on the initial months of therapy.","PeriodicalId":46585,"journal":{"name":"British Journal of Pain","volume":"1 1","pages":""},"PeriodicalIF":1.8,"publicationDate":"2023-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139235722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Investigating self-report and neuropsychological assessments of cognitive flexibility in people with and without persistent pain: An online, cross-sectional, observational study 对有持续性疼痛和无持续性疼痛人群认知灵活性的自我报告和神经心理学评估进行调查:在线横断面观察研究
IF 1.8 Q4 CLINICAL NEUROLOGY Pub Date : 2023-11-21 DOI: 10.1177/20494637231215260
Caitlin A. Howlett, Tyman Stanford, Carolyn Berryman, E. L. Karran, V. Bellan, Scott Coussens, S. Miles, G. L. Moseley
People with persistent pain experience problems modifying their cognition and behaviours when task or environmental demands change – abilities otherwise known as cognitive flexibility. However, limitations and inconsistent results of previous studies raise concerns over the quality of that evidence. We aimed to determine whether people with and without persistent pain differ on two assessments that are commonly used to assess cognitive flexibility. We also examined the relationship between the two assessments and explored whether people with and without persistent pain are distinguishable based on their scores on these assessments. Participant demographics and symptoms of anxiety and depression were assessed. Participants completed the Cognitive Flexibility Inventory (CFI) and the Wisconsin Card Sorting Test (WCST). Multiple linear regression on the two outcome variables: CFI (total score) and WCST (% perseverative responses) was applied using backward stepwise selection. Both outcomes were calculated as a standardised proportion of the outcome scale and log-odds transformed to meet the model assumptions. Correlation analysis and logistic regression were used to investigate our secondary and exploratory aims. Data were available from 128 participants with persistent pain and 68 pain-free controls. After adjusting for covariates, no differences were found between people with and without persistent pain on either assessment of cognitive flexibility. No significant correlations were detected between the two assessments in either group. The probability of having persistent pain was also not associated with scores on either or both assessments. ‘Cognitive flexibility’ appears similar in people with and without persistent pain.
当任务或环境需求发生变化时,持续性疼痛患者会遇到改变认知和行为的问题,这种能力也被称为认知灵活性。然而,以往研究的局限性和不一致的结果引起了人们对证据质量的担忧。我们旨在确定有持续性疼痛的人和没有持续性疼痛的人在两种常用于评估认知灵活性的评估中是否存在差异。我们还研究了这两项评估之间的关系,并探讨了有持续性疼痛的人和没有持续性疼痛的人是否可以根据他们在这些评估中的得分区分开来。我们对参与者的人口统计学特征以及焦虑和抑郁症状进行了评估。参与者完成了认知灵活性量表(CFI)和威斯康星卡片分类测试(WCST)。对两个结果变量进行多元线性回归:采用逆向逐步选择法对 CFI(总分)和 WCST(锲而不舍的反应百分比)这两个结果变量进行多元线性回归。两个结果均按结果量表的标准化比例计算,并进行对数转换以满足模型假设。相关分析和逻辑回归用于研究我们的次要和探索性目标。128名有持续性疼痛的参与者和68名无痛对照者提供了数据。在对协变量进行调整后,发现有持续性疼痛的人和无持续性疼痛的人在认知灵活性的任何一项评估上都没有差异。两组人的这两项评估之间也没有发现明显的相关性。患有持续性疼痛的概率也与其中一项或两项评估的得分无关。有持续性疼痛和无持续性疼痛的人的 "认知灵活性 "似乎相似。
{"title":"Investigating self-report and neuropsychological assessments of cognitive flexibility in people with and without persistent pain: An online, cross-sectional, observational study","authors":"Caitlin A. Howlett, Tyman Stanford, Carolyn Berryman, E. L. Karran, V. Bellan, Scott Coussens, S. Miles, G. L. Moseley","doi":"10.1177/20494637231215260","DOIUrl":"https://doi.org/10.1177/20494637231215260","url":null,"abstract":"People with persistent pain experience problems modifying their cognition and behaviours when task or environmental demands change – abilities otherwise known as cognitive flexibility. However, limitations and inconsistent results of previous studies raise concerns over the quality of that evidence. We aimed to determine whether people with and without persistent pain differ on two assessments that are commonly used to assess cognitive flexibility. We also examined the relationship between the two assessments and explored whether people with and without persistent pain are distinguishable based on their scores on these assessments. Participant demographics and symptoms of anxiety and depression were assessed. Participants completed the Cognitive Flexibility Inventory (CFI) and the Wisconsin Card Sorting Test (WCST). Multiple linear regression on the two outcome variables: CFI (total score) and WCST (% perseverative responses) was applied using backward stepwise selection. Both outcomes were calculated as a standardised proportion of the outcome scale and log-odds transformed to meet the model assumptions. Correlation analysis and logistic regression were used to investigate our secondary and exploratory aims. Data were available from 128 participants with persistent pain and 68 pain-free controls. After adjusting for covariates, no differences were found between people with and without persistent pain on either assessment of cognitive flexibility. No significant correlations were detected between the two assessments in either group. The probability of having persistent pain was also not associated with scores on either or both assessments. ‘Cognitive flexibility’ appears similar in people with and without persistent pain.","PeriodicalId":46585,"journal":{"name":"British Journal of Pain","volume":"38 8","pages":""},"PeriodicalIF":1.8,"publicationDate":"2023-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139251140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Treated versus self-reported prevalence of chronic pain and costs of patients’ health services utilization: a population-based study of health administrative databases 治疗与自我报告的慢性疼痛患病率和患者卫生服务利用成本:一项基于人群的卫生管理数据库研究
Q4 CLINICAL NEUROLOGY Pub Date : 2023-11-07 DOI: 10.1177/20494637231209928
Nguyen Xuan Thanh, Elena Lopatina, Lori S Montgomery, Magali Robert, Robert L Tanguay, Tracy Wasylak
Objectives To compare treated to self-reported prevalence of chronic pain (CP) and to estimate health services utilization (HSU) costs of patients treated for CP in Alberta, Canada. Methods Patients treated for CP were identified by the physician billing codes of health services for CP from the practitioner claims database in fiscal year 2021/22. The treated prevalence of CP (number of these patients divided by the population) was compared to the self-reported prevalence of CP previously estimated (doi:10.1371/journal.pone.0272638). Costs of patients’ HSU included costs for general practitioner (GP), specialist, inpatient, emergency department, outpatient clinic services, and prescription drugs. Results The treated prevalence of CP was 6.0% (4.4% among males and 7.8% among females) which was 30% to 41% of the self-reported prevalence. The highest treated prevalence (7.2%) was found in the age group of 18–64 years, followed by age groups of >64 years (7.0%) and <18 years (2.1%). The average cost per patient per year was $5096 ($5878 for males and $4652 for females), of which hospitalizations accounted for 65.0%, outpatient clinic visits 16.4%, ED visits 9.5%, prescription drugs 4.7%, GP visits 3.9%, and specialist visits 0.4%. The total cost of patients with CP for the health system was $1.37 billion (∼7% of total health expenditure), of which males accounted for 41.7% and females for 58.3%. Discussion Our findings suggest that the economic burden of CP is considerable and that many people with self-reported CP do not use the public healthcare services. This can be multifactorial, including lack of availability and accessibility of publicly funded services, people’s lack of awareness of available services, lower utilization due to COVID-19 pandemic, and reliance on self-management, private services, and alternative treatments. Further studies are warranted to inform future policies and health system initiatives aiming to reduce the burden of CP and improve lives of people living with it.
目的比较治疗后与自我报告的慢性疼痛(CP)患病率,并估计加拿大阿尔伯塔省治疗CP患者的卫生服务利用(HSU)成本。方法采用2021/22会计年度执业理赔数据库中CP卫生服务医师计费代码对CP患者进行识别。将接受治疗的CP患病率(这些患者的数量除以人群)与先前估计的自我报告的CP患病率进行比较(doi:10.1371/journal.pone.0272638)。患者HSU的费用包括全科医生(GP)、专科医生、住院、急诊、门诊服务和处方药的费用。结果经治疗的CP患病率为6.0%(男性4.4%,女性7.8%),占自报患病率的30% ~ 41%。18 - 64岁年龄组治疗患病率最高(7.2%),其次是64岁(7.0%)和18岁(2.1%)年龄组。每位患者每年的平均费用为5096美元(男性5878美元,女性4652美元),其中住院占65.0%,门诊占16.4%,急诊科占9.5%,处方药占4.7%,全科医生占3.9%,专科医生占0.4%。卫生系统对CP患者的总费用为13.7亿美元(约占卫生总支出的7%),其中男性占41.7%,女性占58.3%。我们的研究结果表明,CP的经济负担是相当大的,许多自报CP的人不使用公共医疗服务。这可能是多因素的,包括缺乏公共资助服务的可用性和可及性,人们对现有服务缺乏认识,COVID-19大流行导致利用率降低,以及依赖自我管理、私营服务和替代治疗。有必要进行进一步的研究,为未来的政策和卫生系统举措提供信息,旨在减轻CP的负担,改善患者的生活。
{"title":"Treated versus self-reported prevalence of chronic pain and costs of patients’ health services utilization: a population-based study of health administrative databases","authors":"Nguyen Xuan Thanh, Elena Lopatina, Lori S Montgomery, Magali Robert, Robert L Tanguay, Tracy Wasylak","doi":"10.1177/20494637231209928","DOIUrl":"https://doi.org/10.1177/20494637231209928","url":null,"abstract":"Objectives To compare treated to self-reported prevalence of chronic pain (CP) and to estimate health services utilization (HSU) costs of patients treated for CP in Alberta, Canada. Methods Patients treated for CP were identified by the physician billing codes of health services for CP from the practitioner claims database in fiscal year 2021/22. The treated prevalence of CP (number of these patients divided by the population) was compared to the self-reported prevalence of CP previously estimated (doi:10.1371/journal.pone.0272638). Costs of patients’ HSU included costs for general practitioner (GP), specialist, inpatient, emergency department, outpatient clinic services, and prescription drugs. Results The treated prevalence of CP was 6.0% (4.4% among males and 7.8% among females) which was 30% to 41% of the self-reported prevalence. The highest treated prevalence (7.2%) was found in the age group of 18–64 years, followed by age groups of >64 years (7.0%) and <18 years (2.1%). The average cost per patient per year was $5096 ($5878 for males and $4652 for females), of which hospitalizations accounted for 65.0%, outpatient clinic visits 16.4%, ED visits 9.5%, prescription drugs 4.7%, GP visits 3.9%, and specialist visits 0.4%. The total cost of patients with CP for the health system was $1.37 billion (∼7% of total health expenditure), of which males accounted for 41.7% and females for 58.3%. Discussion Our findings suggest that the economic burden of CP is considerable and that many people with self-reported CP do not use the public healthcare services. This can be multifactorial, including lack of availability and accessibility of publicly funded services, people’s lack of awareness of available services, lower utilization due to COVID-19 pandemic, and reliance on self-management, private services, and alternative treatments. Further studies are warranted to inform future policies and health system initiatives aiming to reduce the burden of CP and improve lives of people living with it.","PeriodicalId":46585,"journal":{"name":"British Journal of Pain","volume":"83 10","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135432958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Confidence of practitioners to support self-management of pain: A multidisciplinary survey 从业人员支持疼痛自我管理的信心:一项多学科调查
Q4 CLINICAL NEUROLOGY Pub Date : 2023-11-04 DOI: 10.1177/20494637231212748
Chris Penlington, Pattramon Pornsukjantra, Paul Chazot, Frances Cole, Diarmuid Denneny
Background Supported self-management is an important component of management for persistent pain according to current recommendations and guidelines. However, it is unclear whether staff from differing disciplines who may be in early contact with people with established or developing persistent pain are confident to introduce and support self-management for this patient group. Aim To determine the confidence of staff across professional disciplines to introduce and support self-management. Design and Setting Cross-sectional online survey. Methods Charts were constructed to represent information on professional grouping, prior training in self-management and confidence in supporting key components of self-management for persistent pain. Analysis of variance was used to test for differences between groups. Results Overall, 165 practitioners reported confidence to support self-management below the midpoint of a ten-point scale and 93 above. There were few differences between different professions apart from in explaining pain (f = 6.879 p < .001), managing activity levels (f = 6.340 p < .001) and supporting healthy habits (f = 4.700, p = .001) in which physiotherapists expressed higher confidence than other professional groups. There was no difference in confidence expressed between staff who had or had not received previous training in self-management (f = 1.357, p = .233). Conclusions Many front-line staff who might be expected to introduce and deliver self-management support for persistent pain lack the confidence and skills to do so. This is consistent with a known lack of education about pain across disciplinary boundaries in primary and community-based care. In order to meet treatment priorities for persistent pain there is an urgent need to upskill the workforce by providing access to good quality training and resources.
背景:根据目前的建议和指南,支持性自我管理是持续性疼痛管理的重要组成部分。然而,目前尚不清楚的是,来自不同学科的工作人员是否有信心为这一患者群体介绍和支持自我管理,这些工作人员可能在早期接触到已有或正在发展的持续性疼痛患者。目的确定各专业人员引入和支持自我管理的信心。设计与设置横断面在线调查。方法构建图表,反映专业分组、先前自我管理培训和对支持持续疼痛自我管理关键组成部分的信心。方差分析用于检验组间差异。结果总体而言,165名从业人员对支持自我管理的信心低于10分制的中点,93名从业人员高于10分制的中点。不同职业之间除了对疼痛的解释差异不大(f = 6.879 p <.001),管理活动水平(f = 6.340 p <.001)和支持健康习惯(f = 4.700, p = .001)在这方面,物理治疗师比其他专业群体表现出更高的信心。在之前接受过或没有接受过自我管理培训的员工之间,信心表达没有差异(f = 1.357, p = 0.233)。结论许多一线工作人员可能会对持续性疼痛进行自我管理支持,但他们缺乏这样做的信心和技能。这与在初级和社区护理中缺乏跨学科疼痛教育是一致的。为了满足对持续性疼痛的优先治疗,迫切需要通过提供高质量的培训和资源来提高工作人员的技能。
{"title":"Confidence of practitioners to support self-management of pain: A multidisciplinary survey","authors":"Chris Penlington, Pattramon Pornsukjantra, Paul Chazot, Frances Cole, Diarmuid Denneny","doi":"10.1177/20494637231212748","DOIUrl":"https://doi.org/10.1177/20494637231212748","url":null,"abstract":"Background Supported self-management is an important component of management for persistent pain according to current recommendations and guidelines. However, it is unclear whether staff from differing disciplines who may be in early contact with people with established or developing persistent pain are confident to introduce and support self-management for this patient group. Aim To determine the confidence of staff across professional disciplines to introduce and support self-management. Design and Setting Cross-sectional online survey. Methods Charts were constructed to represent information on professional grouping, prior training in self-management and confidence in supporting key components of self-management for persistent pain. Analysis of variance was used to test for differences between groups. Results Overall, 165 practitioners reported confidence to support self-management below the midpoint of a ten-point scale and 93 above. There were few differences between different professions apart from in explaining pain (f = 6.879 p < .001), managing activity levels (f = 6.340 p < .001) and supporting healthy habits (f = 4.700, p = .001) in which physiotherapists expressed higher confidence than other professional groups. There was no difference in confidence expressed between staff who had or had not received previous training in self-management (f = 1.357, p = .233). Conclusions Many front-line staff who might be expected to introduce and deliver self-management support for persistent pain lack the confidence and skills to do so. This is consistent with a known lack of education about pain across disciplinary boundaries in primary and community-based care. In order to meet treatment priorities for persistent pain there is an urgent need to upskill the workforce by providing access to good quality training and resources.","PeriodicalId":46585,"journal":{"name":"British Journal of Pain","volume":"11 5","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135774514","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
British Journal of Pain
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1